MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 54-05-7
MCE 国际站:Chloroquine
产品活性:Chloroquine 是一种广泛用于疟疾和类风湿性关节炎的抗炎试剂。Chloroquine 是自噬 (autophagy) 和 Toll 样受体 (TLRs) 的抑制剂。Chloroquine 有效抑制 SARS-CoV-2 (COVID-19) 感染 (EC50=1.13 μM)。
研究领域:Autophagy | Anti-infection | Immunology/Inflammation
作用靶点:Parasite | Autophagy | SARS-CoV | Toll-like Receptor (TLR) | HIV | Antibiotic
In Vitro: Chloroquine (CHQ, 20 μM) inhibits IL-12p70 release and reduces Th1-priming capacity of activated human monocyte-derived Langerhans-like cells (MoLC). Chloroquine (20 μM) enhances IL-1–induced IL-23 secretion in MoLC and subsequently increases IL-17A release by primed CD4+ T cells. Chloroquine (25 μM) suppresses MMP-9 mRNA expression in normoxia and hypoxia in parental MDA-MB-231 cells. Chloroquine has cell-, dose- and hypoxia-dependent effects on MMP-2, MMP-9 and MMP-13 mRNA expression. TLR7 and TLR9 inhibition using IRS-954 or chloroquine significantly reduces HuH7 cell proliferation in vitro.
?Chloroquine (0.01-100 μM; 48?hours) potently blocked virus infection (vero E6 cells infected with SARS-CoV-2) at low-micromolar concentration (EC50=1.13?μM). Chloroquine blocks virus infection by increasing endosomal pH required for virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV.
In Vivo: Chloroquine (80 mg/kg, i.p.) does not prevent the growth of the triple-negative MDA-MB-231 cells with high or low TLR9 expression levels in the orthotopic mouse model.
?TLR7 and TLR9 inhibition using IRS-954 or chloroquine significantly inhibits tumour growth in the mouse xenograft model. HCC development in the DEN/NMOR rat model is also significantly inhibited by Chloroquine.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Antiviral Compound Library | Autophagy Compound Library | Small Molecule Immuno-Oncology Compound Library | Drug Repurposing Compound Library | Antioxidant Compound Library | Differentiation Inducing Compound Library | Oxygen Sensing Compound Library | Pyroptosis Compound Library | FDA Approved & Pharmacopeial Drug Library | Antibiotics Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Antiparasitic Compound library | Rare Diseases Drug Library | Children’s Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Non-steroidal Anti-Inflammatory Compound Library | Heterocyclic Compound Library | Pain-Related Compound Library | Off-patent Drug Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Antifungal agent 26 | C29 | (1R,2S,7R)-Sitafloxacin-d4 hydrochloride | Quinidine-d3 | Angulatin G | Acridine Orange base | N-Desethyl amodiaquine-d5 | Doxorubicin-13C,d3 TFA | Palitantin | Antibiotic A-33853 | Sulbactam-d2 sodium | Peldesine dihydrochloride | Proguanil-d6 | Azlocillin sodium salt | Abacavir sulfate | Toyocamycin | HIV-IN-6 | Methyl palmitate | Hispolon | Epicoccone B | SPR206 acetate | Antimicrobial agent-10 | HBPC–GSH | Doxycycline calcium | Staurosporine | Dihydrostreptomycin sulfate | SARS-CoV-2-IN-23 | Ditiocarb | ODN 1018
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。